Atherogenic lipoprotein particles can vary considerably in their cholesterol content, but each particle contains only one molecule of apoB-100 (or simply apoB). As a result, serum concentration of ...
Twice-yearly inclisiran (Leqvio) monotherapy showed clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of atherosclerotic cardiovascular disease in ...
Aim Low-density lipoprotein cholesterol (LDL-C) goal attainment remains suboptimal among individuals with or at risk for atherosclerotic cardiovascular disease (ASCVD). We evaluated contemporary ...
NewAmsterdam Pharma is rated a Hold and has seen a near 40% stock pullback post-Merck’s Lipfendra approval. Read more on NAMS ...
However, the association between familial hypercholesterolemia variants and coronary heart disease slightly weakened after adjusting for baseline low-density lipoprotein cholesterol (LDL-C) level and ...
Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) ...
Patients were randomly assigned to receive either evolocumab 140 mg every 2 weeks for one year, with the first dose ...
Repatha, also known as evolocumab, was first approved by the FDA in 2015 to help patients lower their LDL, or “bad,” ...
BACKGROUND: Although the effectiveness of Lp(a) (lipoprotein[a])–lowering therapies remains under study, lipid guidelines now ...
Mass General Brigham Heart and Vascular Institute researchers have found that high-risk patients who had not previously ...
In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...
Researchers have designed a new DNA-based treatment that targets PCSK9, a protein closely tied to high LDL cholesterol and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results